➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Mallinckrodt
Harvard Business School
Merck
Express Scripts

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SEROMYCIN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Seromycin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00182000 Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy Completed Hartford Hospital Phase 3 2003-11-01 This study will assess the effectiveness of Seromycin (D-cycloserine) in enhancing the positive effects of behavior therapy for people with Obsessive-Compulsive Disorder (OCD).
NCT00182000 Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy Completed Massachusetts General Hospital Phase 3 2003-11-01 This study will assess the effectiveness of Seromycin (D-cycloserine) in enhancing the positive effects of behavior therapy for people with Obsessive-Compulsive Disorder (OCD).
NCT00198120 Safety and Effectiveness of D-Cycloserine in Children With Autism Completed Indiana University School of Medicine Phase 3 2004-02-01 This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.
NCT00198120 Safety and Effectiveness of D-Cycloserine in Children With Autism Completed National Alliance for Research on Schizophrenia and Depression Phase 3 2004-02-01 This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Seromycin

Condition Name

Condition Name for Seromycin
Intervention Trials
Obsessive-Compulsive Disorder 3
Schizophrenia 3
Major Depressive Disorder 2
Posttraumatic Stress Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Seromycin
Intervention Trials
Disease 7
Depressive Disorder 4
Depression 4
Obsessive-Compulsive Disorder 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Seromycin

Trials by Country

Trials by Country for Seromycin
Location Trials
United States 24
Israel 3
Canada 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Seromycin
Location Trials
Massachusetts 5
Texas 2
Florida 2
New York 2
Indiana 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Seromycin

Clinical Trial Phase

Clinical Trial Phase for Seromycin
Clinical Trial Phase Trials
Phase 4 7
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Seromycin
Clinical Trial Phase Trials
Completed 14
Recruiting 4
Unknown status 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Seromycin

Sponsor Name

Sponsor Name for Seromycin
Sponsor Trials
Massachusetts General Hospital 5
National Institute of Mental Health (NIMH) 5
National Alliance for Research on Schizophrenia and Depression 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Seromycin
Sponsor Trials
Other 38
NIH 9
Industry 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
McKinsey
Medtronic
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.